Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Long-Term Investments (2020 - 2025)

HCW Biologics (HCWB) has disclosed Long-Term Investments for 6 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Investments fell 17.09% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Sep 2025, down 17.09%, and an annual FY2024 reading of $1.6 million, changed 0.0% over the prior year.
  • Long-Term Investments was $1.3 million for Q3 2025 at HCW Biologics, down from $3.3 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $11.6 million in Q3 2021 and bottomed at $1.3 million in Q3 2025.
  • Average Long-Term Investments over 5 years is $4.3 million, with a median of $1.6 million recorded in 2022.
  • The sharpest move saw Long-Term Investments surged 618.86% in 2021, then plummeted 86.09% in 2022.
  • Year by year, Long-Term Investments stood at $11.5 million in 2021, then tumbled by 86.09% to $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024, then decreased by 17.09% to $1.3 million in 2025.
  • Business Quant data shows Long-Term Investments for HCWB at $1.3 million in Q3 2025, $3.3 million in Q2 2025, and $1.6 million in Q1 2025.